Hippo Signaling Pathway in Neurodegeneration

Hippo Signaling Pathway in Neurodegeneration

Overview Diagram

```mermaid
flowchart TB
subgraph Upstream_Inputs["Upstream Signals"]
direction LR
M1["Mechanical<br/>Stress"] --> TAOK1
M2["Cell<br/>Polarity"] --> TAOK1
M3["Energy<br/>Status"] --> AMPK
M4["Neuronal<br/>Activity"] --> NMDA
M5["Oxidative<br/>Stress"] --> ROS
end

subgraph Core_Kinase_Cascade["Core Kinase Cascade"]
direction TB
TAOK1 -->|"Phosphorylates"| MST1["MST1/2<br/>Hippo Kinase"]
AMPK -->|"Phosphorylates"| MST1
NMDA -->|"Activates"| MST1
ROS -->|"Activates"| MST1

MST1 -->|"Phosphorylates"| SAV1["SAV1"]
MST1 -->|"Phosphorylates"| MOB1["MOB1"]

SAV1 & MOB1 -->|"Activate"| LATS["LATS1/2"]
LATS -->|"Phosphorylates"| YAP["YAP/TAZ"]
end

subgraph Regulation["Regulation"]
direction LR
YAP -->|"Nuclear<br/>Translocation"| TEAD["TEAD<br/>Transcription<br/>Factor"]
YAP -->|"Phospho<br/>Cytoplasmic"| P_YAP["Phospho-YAP<br/>(Inactive)"]
P_YAP -->|"14-3-3<br/>Binding"| CYTO["Cytoplasm"]
end

subgraph Downstream_Outcomes["Cellular Outcomes"]
direction LR
TEAD -->|"Pro-survival<br/>Genes"| SURVIVE["Neuronal<br/>Survival"]
TEAD -->|"Neurogenesis<br/>Genes"| NEURO["Adult<br/>Neurogenesis"]
TEAD -->|"Synaptic<br/>Genes"| SYNAPSE["Synaptic<br/>Plasticity"]
TEAD -->|"Regeneration<br/>Genes"| REGEN["Axon<br/>Regeneration"]
end

Hippo Signaling Pathway in Neurodegeneration

Overview Diagram

Introduction

The Hippo signaling pathway, originally discovered in Drosophila melanogaster as a regulator of organ size, has emerged as a critical regulator of neuronal survival, neurogenesis, and synaptic plasticity in the mammalian central nervous system. Named after the Drosophila gene "hippo" whose overexpression causes excessive cell proliferation leading to organ overgrowth, this pathway coordinates cell growth, proliferation, apoptosis, and stem cell self-renewal through a kinase cascade that ultimately controls the activity of transcriptional co-activators YAP and TAZ. [@klaus2020]

In the context of neurodegeneration, Hippo pathway components are expressed in neurons and glia, and dysregulation of this pathway contributes to neuronal death, impaired neurogenesis, and failed regeneration in Alzheimer's disease, Parkinson's disease, and other conditions. The recognition of Hippo pathway involvement in neurodegeneration has opened new therapeutic avenues targeting this pathway. [@kanai2010]

Molecular Components of the Hippo Pathway

The Core Kinase Cascade

The Hippo pathway was originally identified in Drosophila as a size-control mechanism that limits organ growth through a conserved kinase cascade. In mammals, the core pathway consists of MST1/2 (mammalian Ste20-like kinases 1 and 2, also known as Hippo), SAV1 (Sav family member), LATS1/2 (Large tumor suppressor kinases), and MOB1 (MOB kinase activator). [@zhao2008]

MST1 and MST2 are the upstream kinases of the pathway, and they are activated by autophosphorylation and phosphorylation by upstream activators such as TAOK1 (TAO kinase 1). Once activated, MST1/2 phosphorylate and activate the adaptor proteins SAV1 and MOB1, which then facilitate the activation of LATS1/2. [@kim2015]

LATS1 and LATS2 are the key effectors of the pathway that directly phosphorylate the downstream targets YAP (Yes-associated protein) and TAZ (WW domain-containing transcription regulator protein 1). Phosphorylation of YAP/TAZ at multiple sites controls their activity, localization, and stability. [@pobbati2020]

YAP and TAZ: Transcriptional Co-activators

YAP and TAZ are the primary effectors of the Hippo pathway, functioning as transcriptional co-activators that regulate gene expression in response to mechanical and biochemical signals. When the Hippo pathway is active, LATS1/2 phosphorylate YAP at Ser127 and TAZ at Ser89, promoting their retention in the cytoplasm by binding to 14-3-3 proteins. [@wang2018]

When the Hippo pathway is inactive, unphosphorylated YAP/TAZ translocate to the nucleus, where they interact with transcription factors including TEAD (TEA domain) family members to promote the expression of genes involved in cell proliferation, survival, and differentiation. The TEAD-YAP complex is the major transcriptionally active form, and blocking this interaction inhibits YAP-mediated transcription. [@dupont2011]

YAP and TAZ can also be regulated through phosphorylation-independent mechanisms, including protein stability control, subcellular localization, and protein-protein interactions. The diversity of regulatory mechanisms allows fine-tuning of YAP/TAZ activity in response to various cellular signals. [@arden2008]

Hippo Pathway Regulation

Mechanical Cues and Cell Polarity

The Hippo pathway is highly responsive to mechanical forces and cell-cell contact, providing a mechanism for cells to sense their physical environment. Actin cytoskeleton tension and cell geometry influence Hippo pathway activity through mechanisms that remain incompletely understood. Cells spread on large substrates show reduced Hippo pathway activity, while cramped or confined cells exhibit pathway activation. [@wong2013]

Cell polarity proteins including AMOT (Angiomotin), PATJ, and Crumbs can regulate the Hippo pathway by facilitating LATS activation or directly sequestering YAP in the cytoplasm. The Scribble complex (Scribble, Dlg, Lgl) and the Par complex (Par3, Par6, aPKC) provide spatial cues that influence Hippo pathway activity at cell junctions. [@moleirinho2013]

Metabolic and Energy Sensing

The Hippo pathway integrates metabolic status through multiple mechanisms. AMP-activated protein kinase (AMPK), the cellular energy sensor, can phosphorylate both MST1/2 and YAP, providing a link between energy status and Hippo pathway activity. This connection is particularly relevant in neurons, which have high and continuous energy demands. [@grzeschik2010]

Glucose availability influences Hippo pathway activity through the hexosamine biosynthesis pathway, which modifies YAP and regulates its transcriptional activity. The pathway also responds to oxidative stress, with several components being redox-sensitive. These metabolic links position the Hippo pathway as a sensor of cellular fitness that can trigger apoptosis when conditions are unfavorable. [@miller2019]

Neuronal Activity and Synaptic Signaling

Neuronal activity modulates Hippo pathway activity in both developmental and adult contexts. Depolarization of neurons leads to YAP nuclear translocation and activation of target genes, suggesting that activity-dependent signaling influences the pathway. The NMDA receptor and calcium signaling are involved in activity-dependent regulation of YAP in neurons. [@wang2015]

At synapses, YAP and TAZ are present in both pre-synaptic and post-synaptic compartments, where they may regulate synaptic plasticity-related gene expression. The pathway may thus provide a feedback mechanism linking neuronal activity to the expression of survival and plasticity genes. [@watson2010]

Hippo Pathway in Alzheimer's Disease

Amyloid-Beta and YAP Dysregulation

In Alzheimer's disease, amyloid-beta (Aβ) peptide accumulation triggers alterations in Hippo pathway signaling that contribute to neuronal vulnerability. Aβ treatment leads to YAP phosphorylation and cytoplasmic retention, reducing its transcriptional activity in neurons. This loss of YAP function may contribute to the failure of neuroprotective signaling in AD. [@fustinana2013]

The decreased YAP activity in AD is associated with reduced expression of pro-survival genes that normally protect neurons from various stresses. Interestingly, forced YAP activation can protect neurons from Aβ-induced toxicity, suggesting that enhancing YAP activity could be therapeutic in AD. [@shen2018]

Tau Pathology and Hippo Signaling

Hyperphosphorylated tau, the component of neurofibrillary tangles, also interacts with Hippo pathway components. Tau can bind to and sequester MST1 in the cytoplasm, reducing its kinase activity and disrupting downstream signaling. This interaction provides a mechanism by which tau pathology could amplify neuronal dysfunction beyond the direct effects of tau aggregation. [@thompson2015]

The interplay between tau and the Hippo pathway is bidirectional, as YAP can influence tau phosphorylation through effects on tau kinases and phosphatases. This complex relationship suggests that targeting the Hippo pathway could potentially interrupt the vicious cycle of tau pathology progression. [@mischel2017]

Neurogenesis and Hippocampal Function

Adult hippocampal neurogenesis, which is impaired in Alzheimer's disease, is regulated by the Hippo pathway. YAP activity in neural stem cells promotes proliferation and survival, while pathway activation reduces neurogenesis. The decline in neurogenesis observed in AD may thus involve Hippo pathway dysregulation. [@zhang2019]

In the hippocampus, YAP is required for synaptic plasticity and memory formation. Mice with neuronal YAP deficiency show impaired long-term potentiation and defective spatial memory, phenotypes that are reversed by YAP re-expression. These findings highlight the importance of Hippo signaling for hippocampal function beyond its effects on neurogenesis. [@gomezsuaga2018]

Hippo Pathway in Parkinson's Disease

Alpha-Synuclein and YAP

In Parkinson's disease, alpha-synuclein aggregation is associated with altered Hippo pathway signaling. Misfolded alpha-synuclein can activate LATS1/2, leading to increased YAP phosphorylation and cytoplasmic retention. This effect may contribute to the vulnerability of dopaminergic neurons by reducing pro-survival signaling. [@gomezsuaga2019]

Interestingly, YAP can regulate alpha-synuclein expression at the transcriptional level, creating a potential feedback loop between Hippo pathway activity and synucleinopathy. Strategies to modulate this axis may therefore have beneficial effects on multiple aspects of PD pathology. [@chen2020]

Mitochondrial Dysfunction and the Pathway

Mitochondrial dysfunction is a central feature of PD, and the Hippo pathway responds to mitochondrial stress. Mitochondrial toxins that are used to model PD activate the Hippo pathway and increase YAP phosphorylation. This activation may represent an attempt to trigger cell death in damaged neurons. [@liu2018]

Conversely, activation of the Hippo pathway in dopaminergic neurons increases their sensitivity to mitochondrial toxins, suggesting that pathway modulation could influence neuronal vulnerability in PD. Interventions that inhibit Hippo pathway activation may therefore protect dopaminergic neurons from various insults. [@zhang2019a]

LRRK2 and Hippo Signaling

LRRK2 (leucine-rich repeat kinase 2) mutations are a common cause of familial PD, and recent evidence suggests interactions between LRRK2 and Hippo signaling. LRRK2 can phosphorylate LATS1, potentially linking the two pathways in disease contexts. The nature of this interaction and its relevance to PD pathogenesis are actively being investigated. [@li2017]

Hippo Pathway in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

In amyotrophic lateral sclerosis (ALS), Hippo pathway dysregulation has been observed in both motor neurons and supporting glial cells. Activation of the pathway is seen in motor neurons from ALS patients and in models of the disease. The pathway may contribute to the selective vulnerability of motor neurons through effects on cellular stress responses. [@wang2016]

Huntington's Disease

Huntington's disease involves mutant huntingtin protein that acquires toxic functions and impairs cellular homeostasis. The Hippo pathway is dysregulated in HD models, with decreased YAP activity contributing to reduced pro-survival signaling. Enhancing YAP activity can protect neurons from mutant huntingtin toxicity. [@huang2018]

Frontotemporal Dementia

Frontotemporal dementia and related disorders show altered Hippo pathway signaling in affected brain regions. The pathway may interact with tau pathology in these conditions, similar to its role in Alzheimer's disease. Understanding these relationships may reveal shared therapeutic targets across different neurodegenerative conditions. [@sontag2013]

Therapeutic Targeting of the Hippo Pathway

Small Molecule Activators

Several small molecules that enhance YAP/TAZ activity are being developed for neurodegenerative diseases. These include agents that inhibit the upstream kinases LATS1/2 and compounds that prevent YAP phosphorylation and degradation. The challenge is to achieve neuroprotective effects without promoting unwanted cell proliferation. [@sontag2014]

Gene Therapy Approaches

Viral vector-mediated delivery of YAP or inhibition of upstream pathway components represents another therapeutic strategy. Adeno-associated virus (AAV) vectors can target neurons in specific brain regions, and this approach has shown promise in animal models. Safety concerns related to YAP's oncogenic potential require careful consideration and monitoring. [@gendron2019]

Targeting Upstream Regulators

Modulating upstream regulators of the Hippo pathway offers an alternative approach with potentially fewer safety concerns. Mechanical signaling, metabolic sensing, and synaptic activity can all influence the pathway, providing multiple points of intervention. Lifestyle interventions that reduce metabolic stress and maintain synaptic activity may support Hippo pathway function in aging brains. [@zhang2018]

Cross-Linking with Other Pathways

Interaction with Wnt Signaling

The Hippo and Wnt signaling pathways converge on common transcriptional targets and can modulate each other's activity. In neurons, cross-talk between these pathways influences neurogenesis, synapse formation, and plasticity. The convergence of these pathways provides additional points for therapeutic intervention. [@ballatore2007]

Connections to mTOR Signaling

The Hippo pathway and mTOR signaling share regulatory relationships and downstream effectors. Both pathways respond to nutrient and growth factor availability, and they can antagonize or cooperate depending on context. Understanding these interactions may lead to combination therapies that target both pathways. [@song2020]

Integration with Apoptotic Pathways

MST1 is activated by apoptotic stimuli and directly phosphorylates YAP to promote its pro-apoptotic functions. This activation provides a mechanism for connecting external death signals to transcriptional responses that execute apoptosis. In neurodegeneration, this pathway may be abnormally activated, contributing to excessive neuronal death. [@li2019]

Future Directions

The role of the Hippo pathway in neurodegeneration is an emerging area of research with significant therapeutic potential. Further understanding of cell-type-specific pathway regulation, development of brain-penetrant modulators, and identification of biomarkers for patient selection will be critical for clinical translation. The integration of Hippo pathway targeting with other therapeutic strategies may provide synergistic benefits for neurodegenerative disease treatment. [@morenojimenez2019]

Pathway Diagram

The following diagram shows the key molecular relationships involving Hippo Signaling Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: